Nasdaq · CIK 0000879169
INCY INCYTE CORP
Insider trading from SEC Form 4. Last filing 7 d ago. Close $112.79 on Oct 9, 2026, +35% from the 52-week low and -13% from the high.
Last 90 days
Net insider value
-$2.8M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
1
$2.8M by 1 insider
Insiders on file
19
with a Form 4 at this company
Price and insider trades, last year
INCYOct 9, 2026 · close 112.79
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at INCYTE CORP, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Pablo J Cagnoni President, Global Head of R&D sell | $2.8M 23,218 shares | -11% | - | |
| 38Weak | Barry P Flannelly EVP & General Manager US sell | $1.3M 19,807 shares | -37% | - | |
| 0Weak | Sheila A. Denton EVP & General Counsel sell | $42k 599 shares | -2% | - | |
| 15Weak | Sheila A. Denton EVP & General Counsel sell | $1.0M 14,069 shares | -35% | - | |
| 24Weak | Steven H Stein EVP & Chief Medical Officer sell | $898k 12,352 shares | -16% | - | |
| 12Weak | Thomas Tray Principal Accounting Officer sell | $91k 1,300 shares | -5% | - | |
| 25Weak | Vijay K Iyengar EVP, GMAPPS sell | $456k 6,043 shares | -16% | - | |
| 0Weak | Barry P Flannelly EVP & General Manager US sell | $293k 3,680 shares | -6% | - |
Congressional trades
1 trade in INCY disclosed by members of Congress under the STOCK Act. All congressional trades.
| Member | Trade | Asset | Reported range | Trade / filing date | Source |
|---|---|---|---|---|---|
Robert P. Bresnahan, Jr. House · R-PA | Sale | INCY Incyte Corporation - Common Stock | $1,001 to $15k | May 15, 2025 / May 31, 2025 16 days after the trade | Clerk |
Transactions
The last 72 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Lee Heeson EVP, Head of Incyte Intl | FTax withholding Common Stock | -463 | $117.14 | $54k | 37,578 | 7 d ago |
| Sep 30, 2026 | Baker Bros. Advisors LP director, owner | AGrant or award Common Stockindirect: See Footnotes | +322 | $0.00 | $0 | 2,835,403 | 10 d ago |
| Sep 30, 2026 | Edmund Harrigan director | AGrant or award Common Stock10b5-1 | +206 | $121.35 | $25k | 23,225 | 10 d ago |
| Sep 30, 2026 | Paul J Clancy director | AGrant or award Common Stock10b5-1 | +203 | $121.35 | $25k | 25,838 | 10 d ago |
| Sep 30, 2026 | Baker Bros. Advisors LP director, owner | AGrant or award Common Stockindirect: See Footnotes | +322 | $0.00 | $0 | 28,206,082 | 10 d ago |
| Sep 22, 2026 | David H Gardner EVP, Chief Strategy Officer | FTax withholding Common Stock | -920 | $126.93 | $117k | 15,904 | 18 d ago |
| Sep 15, 2026 | Pablo J Cagnoni President, Global Head of R&D | MOption exercise Common Stock10b5-1 | +2,957 | $61.76 | $183k | 186,157 | 25 d ago |
| Sep 15, 2026 | Pablo J Cagnoni President, Global Head of R&D | MOption exercise Common Stock10b5-1 | +4,551 | $61.18 | $278k | 190,708 | 25 d ago |
| Sep 15, 2026 | Pablo J Cagnoni President, Global Head of R&D | MOption exercise Common Stock10b5-1 | +6,477 | $64.25 | $416k | 197,185 | 25 d ago |
| Sep 15, 2026 | Pablo J Cagnoni President, Global Head of R&D | MOption exercise Common Stock10b5-1 | +9,233 | $71.93 | $664k | 206,418 | 25 d ago |
| Sep 15, 2026 | Pablo J Cagnoni President, Global Head of R&D | SOpen-market sale Common Stock10b5-1 | -9,233 | $120.50 | $1.1M | 197,185 | 25 d ago |
| Sep 15, 2026 | Pablo J Cagnoni President, Global Head of R&D | SOpen-market sale Common Stock10b5-1 | -13,985 | $120.49 | $1.7M | 183,200 | 25 d ago |
| Sep 15, 2026 | Pablo J Cagnoni President, Global Head of R&D | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -2,957 | $0.00 | $0 | 4,225 | 25 d ago |
| Sep 15, 2026 | Pablo J Cagnoni President, Global Head of R&D | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -4,551 | $0.00 | $0 | 4,551 | 25 d ago |
| Sep 15, 2026 | Pablo J Cagnoni President, Global Head of R&D | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -6,477 | $0.00 | $0 | 20,356 | 25 d ago |
| Sep 15, 2026 | Pablo J Cagnoni President, Global Head of R&D | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -9,233 | $0.00 | $0 | 18,466 | 25 d ago |
| Jun 10, 2025 | Jean Jacques Bienaime director | AGrant or award Common Stock | +2,518 | $0.00 | $0 | 20,841 | Jun 12, 2025 |
| Jun 10, 2025 | Otis W Brawley director | AGrant or award Common Stock | +2,518 | $0.00 | $0 | 11,252 | Jun 12, 2025 |
| Jun 10, 2025 | Baker Bros. Advisors LP director, owner | AGrant or award Common Stockindirect: See Footnotes | +2,518 | $0.00 | $0 | 2,816,410 | Jun 12, 2025 |
| Jun 10, 2025 | Baker Bros. Advisors LP director, owner | AGrant or award Common Stockindirect: See Footnotes | +2,518 | $0.00 | $0 | 28,187,089 | Jun 12, 2025 |
| Jun 10, 2025 | Jean Jacques Bienaime director | AGrant or award Non Qualfied Stock Option (right to buy)derivative | +9,216 | $0.00 | $0 | 9,216 | Jun 12, 2025 |
| Jun 10, 2025 | Otis W Brawley director | AGrant or award Non Qualfied Stock Option (right to buy)derivative | +9,216 | $0.00 | $0 | 9,216 | Jun 12, 2025 |
| Jun 10, 2025 | Baker Bros. Advisors LP director, owner | AGrant or award Non- Qualified Stock Options (right to buy)derivativeindirect: See Footnotes | +9,216 | $0.00 | $0 | 9,216 | Jun 12, 2025 |
| Jun 10, 2025 | Baker Bros. Advisors LP director, owner | AGrant or award Non- Qualified Stock Options (right to buy)derivativeindirect: See Footnotes | +9,216 | $0.00 | $0 | 9,216 | Jun 12, 2025 |
| Mar 31, 2025 | Baker Bros. Advisors LP director, owner | AGrant or award Common Stockindirect: See Footnotes | +487 | $0.00 | $0 | 2,813,892 | Apr 2, 2025 |
| Mar 31, 2025 | Baker Bros. Advisors LP director, owner | AGrant or award Common Stockindirect: See Footnotes | +487 | $0.00 | $0 | 28,184,571 | Apr 2, 2025 |
| Mar 25, 2025 | Matteo Trotta EVP, GM, Dermatology US | FTax withholding Common Stock | -537 | $62.08 | $33k | 9,937 | Mar 27, 2025 |
| Mar 14, 2025 | Barry P Flannelly EVP & General Manager US | SOpen-market sale Common Stock10b5-1 | -461 | $67.85 | $31k | 52,913 | Mar 18, 2025 |
| Mar 14, 2025 | Barry P Flannelly EVP & General Manager US | SOpen-market sale Common Stock10b5-1 | -199 | $67.88 | $14k | 52,714 | Mar 18, 2025 |
| Mar 14, 2025 | Barry P Flannelly EVP & General Manager US | SOpen-market sale Common Stock10b5-1 | -19,147 | $67.68 | $1.3M | 33,567 | Mar 18, 2025 |
| Mar 4, 2025 | Sheila A. Denton EVP & General Counsel | MOption exercise Common Stock10b5-1 | +599 | $58.06 | $35k | 26,447 | Mar 6, 2025 |
| Mar 4, 2025 | Sheila A. Denton EVP & General Counsel | SOpen-market sale Common Stock10b5-1 | -599 | $69.99 | $42k | 25,848 | Mar 6, 2025 |
| Mar 4, 2025 | Sheila A. Denton EVP & General Counsel | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -599 | $0.00 | $0 | 18,552 | Mar 6, 2025 |
| Feb 26, 2025 | Sheila A. Denton EVP & General Counsel | MOption exercise Common Stock10b5-1 | +9,574 | $58.06 | $556k | 39,917 | Feb 28, 2025 |
| Feb 26, 2025 | Sheila A. Denton EVP & General Counsel | SOpen-market sale Common Stock10b5-1 | -9,574 | $74.07 | $709k | 30,343 | Feb 28, 2025 |
| Feb 26, 2025 | Sheila A. Denton EVP & General Counsel | SOpen-market sale Common Stock10b5-1 | -4,495 | $74.08 | $333k | 25,848 | Feb 28, 2025 |
| Feb 26, 2025 | Sheila A. Denton EVP & General Counsel | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -9,574 | $0.00 | $0 | 19,151 | Feb 28, 2025 |
| Jan 31, 2025 | Michael James Morrissey EVP, Head of Tech. Operations | AGrant or award Common Stock | +10,552 | $0.00 | $0 | 81,515 | Feb 3, 2025 |
| Jan 31, 2025 | Lee Heeson EVP, Head of Incyte Intl | AGrant or award Common Stock | +6,331 | $0.00 | $0 | 32,778 | Feb 3, 2025 |
| Jan 21, 2025 | Michael James Morrissey EVP, Head of Tech. Operations | FTax withholding Common Stock | -429 | $73.47 | $32k | 70,963 | Jan 22, 2025 |
| Jan 21, 2025 | Steven H Stein EVP & Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -12,352 | $72.69 | $898k | 66,967 | Jan 22, 2025 |
| Jan 17, 2025 | Pablo J Cagnoni President, R&D | AGrant or award Employee Stock Option (right to buy)derivative | +40,289 | $0.00 | $0 | 40,289 | Jan 22, 2025 |
| Jan 17, 2025 | Sheila A. Denton EVP & General Counsel | AGrant or award Employee Stock Option (right to buy)derivative | +12,086 | $0.00 | $0 | 12,086 | Jan 22, 2025 |
| Jan 17, 2025 | Barry P Flannelly EVP & General Manager US | AGrant or award Employee Stock Option (right to buy)derivative | +20,144 | $0.00 | $0 | 20,144 | Jan 22, 2025 |
| Jan 17, 2025 | Herve Hoppenot Chairman / CEO | AGrant or award Employee Stock Option (right to buy)derivative | +55,510 | $0.00 | $0 | 55,510 | Jan 22, 2025 |
| Jan 17, 2025 | Matteo Trotta EVP, GM, Dermatology US | AGrant or award Employee Stock Option (right to buy)derivative | +5,371 | $0.00 | $0 | 5,371 | Jan 22, 2025 |
| Jan 17, 2025 | Thomas Tray Principal Accounting Officer | AGrant or award Employee Stock Option (right to buy)derivative | +3,432 | $0.00 | $0 | 3,432 | Jan 22, 2025 |
| Jan 17, 2025 | Christiana Stamoulis EVP & Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +25,516 | $0.00 | $0 | 25,516 | Jan 22, 2025 |
| Jan 17, 2025 | Vijay K Iyengar EVP, GMAPPS | AGrant or award Employee Stock Option (right to buy)derivative | +14,772 | $0.00 | $0 | 14,772 | Jan 22, 2025 |
| Jan 17, 2025 | Paula J Swain EVP, Human Resources | AGrant or award Employee Stock Option (right to buy)derivative | +14,772 | $0.00 | $0 | 14,772 | Jan 22, 2025 |
| Jan 17, 2025 | Steven H Stein EVP & Chief Medical Officer | AGrant or award Employee Stock Option (right to buy)derivative10b5-1 | +28,202 | $0.00 | $0 | 28,202 | Jan 22, 2025 |
| Jan 15, 2025 | Michael James Morrissey EVP, Head of Tech. Operations | FTax withholding Common Stock | -908 | $72.46 | $66k | 71,392 | Jan 17, 2025 |
| Jan 15, 2025 | Christiana Stamoulis EVP & Chief Financial Officer | FTax withholding Common Stock | -3,672 | $72.46 | $266k | 91,525 | Jan 17, 2025 |
| Jan 15, 2025 | Barry P Flannelly EVP & General Manager US | FTax withholding Common Stock | -3,158 | $72.46 | $229k | 53,374 | Jan 17, 2025 |
| Jan 15, 2025 | Steven H Stein EVP & Chief Medical Officer | FTax withholding Common Stock | -10,692 | $72.46 | $775k | 79,319 | Jan 17, 2025 |
| Jan 6, 2025 | Mohamed Khairie Issa EVP, Head of US Oncology | AGrant or award Common Stock | +48,671 | $0.00 | $0 | 48,671 | Jan 8, 2025 |
| Dec 31, 2024 | Baker Bros. Advisors LP director, owner | AGrant or award Common Stockindirect: See Footnotes | +446 | $0.00 | $0 | 2,813,405 | Jan 3, 2025 |
| Dec 31, 2024 | Paul J Clancy director | AGrant or award Common Stock10b5-1 | +331 | $69.07 | $23k | 19,713 | Jan 3, 2025 |
| Dec 31, 2024 | Edmund Harrigan director | AGrant or award Common Stock10b5-1 | +339 | $69.07 | $23k | 17,071 | Jan 3, 2025 |
| Dec 31, 2024 | Baker Bros. Advisors LP director, owner | AGrant or award Common Stockindirect: See Footnotes | +446 | $0.00 | $0 | 28,184,084 | Jan 3, 2025 |
| Dec 13, 2024 | Thomas Tray Principal Accounting Officer | SOpen-market sale Common Stock10b5-1 | -650 | $70.64 | $46k | 23,962 | Dec 17, 2024 |
| Dec 16, 2024 | Thomas Tray Principal Accounting Officer | SOpen-market sale Common Stock10b5-1 | -650 | $69.31 | $45k | 23,312 | Dec 17, 2024 |
| Dec 9, 2024 | Barry P Flannelly EVP & General Manager US | FTax withholding Common Stock | -1,510 | $72.11 | $109k | 56,532 | Dec 11, 2024 |
| Dec 9, 2024 | Paula J Swain EVP, Human Resources | FTax withholding Common Stock | -873 | $72.11 | $63k | 85,203 | Dec 11, 2024 |
| Nov 29, 2024 | Vijay K Iyengar EVP, GMAPPS | SOpen-market sale Common Stock10b5-1 | -360 | $75.60 | $27k | 36,341 | Dec 3, 2024 |
| Nov 29, 2024 | Vijay K Iyengar EVP, GMAPPS | SOpen-market sale Common Stock10b5-1 | -5,683 | $75.37 | $428k | 30,658 | Dec 3, 2024 |
| Nov 6, 2024 | Barry P Flannelly EVP & General Manager US | MOption exercise Common Stock10b5-1 | +1,424 | $72.27 | $103k | 59,466 | Nov 8, 2024 |
| Nov 6, 2024 | Barry P Flannelly EVP & General Manager US | MOption exercise Common Stock10b5-1 | +2,256 | $68.62 | $155k | 61,722 | Nov 8, 2024 |
| Nov 6, 2024 | Barry P Flannelly EVP & General Manager US | SOpen-market sale Common Stock10b5-1 | -1,424 | $82.00 | $117k | 60,298 | Nov 8, 2024 |
| Nov 6, 2024 | Barry P Flannelly EVP & General Manager US | SOpen-market sale Common Stock10b5-1 | -2,256 | $78.21 | $176k | 58,042 | Nov 8, 2024 |
| Nov 6, 2024 | Barry P Flannelly EVP & General Manager US | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -1,424 | $0.00 | $0 | 0 | Nov 8, 2024 |
| Nov 6, 2024 | Barry P Flannelly EVP & General Manager US | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -2,256 | $0.00 | $0 | 0 | Nov 8, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Baker Bros. Advisors LPdirector, owner
- Jean Jacques Bienaimedirector
- Otis W Brawleydirector
- Pablo J CagnoniPresident, Global Head of R&D
- Paul J Clancydirector
- Sheila A. DentonEVP & General Counsel
- Barry P FlannellyEVP & General Manager US
- David H GardnerEVP, Chief Strategy Officer
- Edmund Harrigandirector
- Lee HeesonEVP, Head of Incyte Intl
- Herve HoppenotChairman / CEO
- Mohamed Khairie IssaEVP, Head of US Oncology
- Vijay K IyengarEVP, GMAPPS
- Michael James MorrisseyEVP, Head of Tech. Operations
- Paula J SwainEVP, Human Resources
- Christiana StamoulisEVP & Chief Financial Officer
- Steven H SteinEVP & Chief Medical Officer
- Thomas TrayPrincipal Accounting Officer
- Matteo TrottaEVP, GM, Dermatology US
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.